Actavis’ Warner Chilcott Buy Brings Switch Options In Diversified Portfolio
This article was originally published in The Tan Sheet
Executive Summary
Actavis’ acquisition of Warner Chilcott creates a women’s health powerhouse with Rx-to-OTC switch potential. UBS analysts expect $400 million in cost synergies and an “even more robust than previously disclosed” pipeline and diverse product portfolio that complements Actavis’ existing products.